Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
CHYMODIACTIN (chymopapain) is an injectable enzyme derived from papaya that was approved in 1982 for intradiscal injection to treat herniated intervertebral discs. It works by enzymatically digesting the nucleus pulposus of the disc, reducing pressure on nerve roots and alleviating pain. The drug represents an early proteolytic intervention in interventional spine care.
This legacy injectable is in late-stage product life with minimal modern commercial infrastructure; expect small, focused teams managing market maintenance rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CHYMODIACTIN offers stability in a specialized spine niche with minimal growth expectations but deep market knowledge requirements. This is a career fit for professionals focused on operational excellence, legacy product optimization, and specialized physician relationships rather than innovation or large-scale commercial expansion.
Worked on CHYMODIACTIN at Discure Technologies? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.